InduPro Therapeutics announces strategic collaboration with Lilly to develop first-in-class Bispecific/Multispecific oncology therapeutics using InduPro’s proximity-guided platform

CAR-T Digest - August 2020

Weekly Digest - January 2026

7 January 2026: InduPro Therapeutics announces strategic collaboration with Lilly to develop first-in-class Bispecific/Multispecific oncology therapeutics using InduPro’s proximity-guided platform

InduPro entered a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly and Company to discover novel oncology therapeutics using InduPro’s proximity-guided platform
The collaboration will cover up to three oncology targets, with a total potential deal value of approximately $950 million, including milestones, alongside Lilly’s equity investment in InduPro
The partners will leverage InduPro’s Tumor Associated Proximity Antigens (TAPAs) concept to identify spatially co-localized antigen pairs, enabling new approaches for bispecific ADCs and multispecific T-cell engagers with improved safety, potency, and tumor selectivity
Lilly gains access to InduPro’s proprietary AI/ML-enabled membrane interactomics (MInt) platform, while InduPro will lead early discovery and advance bispecific and multispecific antibody programs arising from the collaboration
The partnership reflects growing confidence in proximity-based tumor biology as a differentiated strategy to design next-generation, tumor-selective cancer therapies across multiple modalities